One-carbon is receiving a seed investment

by admin
september 10, 2021

One-carbon is receiving a seed investment from its founders to strengthen the financial situation and secure continuous pre-clinical development of MTHFD2 inhibitors.

Rekommenderade artiklar

Detailed mode of action of the MTHFD1/2 inhibitor TH9619 now published in Nature Metabolism

The One-carbon Therapeutics team is proud and excited to share

We are presenting our novel MTHFD1/2 inhibitor at the DDR inhibitor summit

We are presenting our data at the DDR inhibitor summit,

One-carbon Therapeutics receives US patent

We are happy to announce that on the 22nd of

Menu bar